FY2026 EPS Forecast for Korro Bio Increased by Analyst

Korro Bio, Inc. (NASDAQ:KRRO) – Equities researchers at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for shares of Korro Bio in a research note issued on Friday, November 6th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($4.26) for the year, up from their previous forecast of ($4.88). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($4.92) per share. HC Wainwright also issued estimates for Korro Bio’s Q4 2026 earnings at ($0.73) EPS, Q3 2027 earnings at ($1.25) EPS and FY2027 earnings at ($5.03) EPS.

KRRO has been the subject of a number of other research reports. Jefferies Financial Group set a $15.00 price target on Korro Bio in a research report on Tuesday, October 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Korro Bio in a research report on Friday, October 2nd. Finally, Wall Street Zen raised shares of Korro Bio from a “sell” rating to a “hold” rating in a research note on Saturday. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $16.50.

Korro Bio Stock Performance

KRRO opened at $14.96 on Tuesday. The business’s fifty day moving average is $11.66 and its two-hundred day moving average is $12.08. The company has a market cap of $220.36 million, a price-to-earnings ratio of -1.65 and a beta of 3.23. Korro Bio has a one year low of $5.20 and a one year high of $36.79.

Korro Bio (NASDAQ:KRRO) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.16.

Institutional Investors Weigh In On Korro Bio

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of Korro Bio during the second quarter worth about $10,776,000. Affinity Asset Advisors LLC acquired a new stake in Korro Bio during the first quarter worth approximately $8,002,000. Nantahala Capital Management LLC acquired a new stake in Korro Bio during the second quarter worth approximately $8,699,274. ADAR1 Capital Management LLC acquired a new stake in Korro Bio during the second quarter worth approximately $7,118,000. Finally, Kalehua Capital Management LLC purchased a new stake in Korro Bio in the 1st quarter worth approximately $1,238,000. 13.18% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Korro Bio news, Director Jean Formela sold 28,468 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $14.00, for a total transaction of $398,552.00. Following the completion of the transaction, the director owned 141,053 shares of the company’s stock, valued at approximately $1,974,742. This trade represents a 16.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Oliver Dolan sold 7,347 shares of the business’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $13.51, for a total value of $99,257.97. Following the completion of the transaction, the senior vice president directly owned 16,252 shares of the company’s stock, valued at approximately $219,564.52. This trade represents a 31.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders purchased 79,809 shares of company stock valued at $884,919 and sold 36,126 shares valued at $502,148. 4.80% of the stock is currently owned by company insiders.

About Korro Bio

Korro Bio, Inc is a clinical-stage biotechnology company developing RNA editing medicines for genetically driven diseases. The company’s approach is designed to make targeted changes to messenger RNA, potentially correcting or altering disease-related genetic instructions without permanently changing a patient’s DNA.

Korro Bio’s technology platform uses programmable oligonucleotides to guide RNA editing in specific cells and tissues. Its lead development program, KRRO-110, is being developed for alpha-1 antitrypsin deficiency, an inherited disorder caused by mutations in the SERPINA1 gene that can lead to liver and lung disease.